Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01039636 |
|
Recruitment Status :
Completed
First Posted : December 25, 2009
Last Update Posted : February 10, 2012
|
Sponsor:
FerroKin BioSciences, Inc.
Information provided by (Responsible Party):
FerroKin BioSciences, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this research study is to study the safety of increasing doses of FBS0701, and to see how quickly the study medication is absorbed and how quickly it disappears from the bloodstream. FBS0701 is a new, oral iron chelator - a medication taken by mouth that increases the body's elimination of iron. Iron chelators are used in patients who develop iron overload from their transfusions. Four increasing doses of FBS0701 will be tested during this study. The study will start with the lowest dose given to 4 patients (3 mg/kg/day. The next group of 4 patients will receive the next high dose (8mg/kg/day only after the results of the first 4 patients are examined and it is determined safe to continue. Participating patients will take the study medication for 7 days and be followed for 28 days after their last dose to determine if they have any reactions to the study medication - therefore a total of 35 days on study. Patients will need to give up to 17 blood samples over the screening period and first 15 days of the study (a total of about 9 tablespoons). Patients will not need to stay overnight in the clinic but will need to visit the clinic 10 times for screening and on-study visits over the 35 days. Patients currently taking an iron chelator will need to stop that treatment for up to 22 days (up to 5 days before they start the study and for 15 days during the study). The results of this study will be helpful in determining the safety of the drug and the best doses of FBS0701 to be used in the next study which will assess the effectiveness of this new iron chelator.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Transfusional Iron Overload Beta-thalassemia | Drug: FBS0701 | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 20 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A PHASE 1b OPEN LABEL, MULTI-CENTER, ESCALATING MULTIPLE DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF FBS0701 IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD |
| Study Start Date : | November 2009 |
| Actual Primary Completion Date : | December 2010 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Beta thalassemia
MedlinePlus related topics:
Iron
| Arm | Intervention/treatment |
|---|---|
|
Experimental: FBS0701 - 5 escalating doses
5 escalating doses of FBS0701 in 5 cohorts of 4 patients each.
|
Drug: FBS0701
Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day |
Primary Outcome Measures :
- Safety and tolerability by AEs, Physical Exam, Clinical Laboratory assessments [ Time Frame: 35 days (7 days treatment and 28 days follow up) ]
- Steady state plasma level and half-life of FBS0701 [ Time Frame: 7 days of dosing ]
Secondary Outcome Measures :
- Urinary excretion of iron [ Time Frame: 7 days of dosing ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- At least 18 years old
- Transfusion dependent (at least 8 transfusions per year) with transfusional iron overload needing treatment with deperoxamine, deferasirox or deperiprone.
- Willing to discontinue current iron chelation therapy for 2-5 days prior to enrollment and for a total of up to 3 weeks
- Willing to fast after midnight prior to each dose
- Serum ferritin greater than 400ng/ml
- Liver iron concentration greater than or equal to 1.5 mg iron. (determined by MRI or SQUID within 12 months prior to enrollment)
- Cardiac iron greater than or equal to 12 milliseconds (determined by MRI t2* within 18 months prior to enrollment)
- Mean of last 3 pre-transfusion hemoglobin values must be greater than or equal to 7.5 g/dl
- Agrees to use approved contraception from Screening and until 30 days after last administration of study drug. Abstinence OK.
Exclusion Criteria:
- Principal Investigator considers patient unfit for study after conducting a medical review, physical examination and other screening assessments.
- Non-elective hospitalization with past 30 days
- Evidence of clinically relevant oral, cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric or skin disorder.
- Evidence of significant renal insufficiency; serum creatine above upper limit of normal or proteinuria greater than 2 gm per day or calculated creatinine clearance of less than or equal to 60ml/min
- Platelet count below 150,000,000/ml and/or absolute neutrophil count less then 1500/mm3
- Alkaline phosphatase or AST greater than 5 times the upper limit of normal or ALT greater than 4 times the upper limit of normal
- Female patients who are pregnant or lactating
- Use of any investigational agent within the last 30 days
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01039636
Locations
| United States, California | |
| Children's Hospital of Oakland | |
| Oakland, California, United States, 94609 | |
| United States, Massachusetts | |
| Children's Hospital of Boston | |
| Boston, Massachusetts, United States, 02115 | |
| United States, Pennsylvania | |
| Children's Hospital of Philadelphia | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Australia | |
| Royal Adelaide Hospital | |
| Adelaide, Australia | |
| Thailand | |
| Siriraj Hospital, Mahidol University | |
| Bangkok, Thailand, 10700 | |
Sponsors and Collaborators
FerroKin BioSciences, Inc.
Investigators
| Principal Investigator: | Ellis Neufeld, MD | Boston Children's Hospital |
| Responsible Party: | FerroKin BioSciences, Inc. |
| ClinicalTrials.gov Identifier: | NCT01039636 |
| Other Study ID Numbers: |
FBS0701-CTP-03 |
| First Posted: | December 25, 2009 Key Record Dates |
| Last Update Posted: | February 10, 2012 |
| Last Verified: | January 2011 |
Keywords provided by FerroKin BioSciences, Inc.:
|
Beta-thalassemia Sickle cell anemia Transfusional iron overload Iron overload Iron chelation |
Additional relevant MeSH terms:
|
Thalassemia beta-Thalassemia Iron Overload Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia |
Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn Iron Metabolism Disorders Metabolic Diseases |